Securities Analyst Recommendations: InfuSystem Holdings Inc. (INFU), Ingevity Corporation (NGVT)

InfuSystem Holdings Inc. (NYSE:INFU) tinted gains of +1.79% (+0.07 points) to US$3.98. The volume of 0.11 Million shares climbed down over an trading activity of 15.17 Million shares. EPS ratio determined by looking at last 12 month figures is -0.08. Over the same time span, the stock marked US$4 as its best level and the lowest price reached was US$2.2. The corporation has a market cap of US$77.77 Million.

InfuSystem Holdings Inc. (NYSE:INFU)’s earnings per share has been growing at a -18.6 percent rate over the past 5 year when average revenue increase was noted as 3.9 percent. The return on equity ratio or ROE stands at -66.9 percent while most common profitability ratio return on investment (ROI) was -3.8 percent. The company’s institutional ownership is monitored at 65.6 percent. The company’s net profit margin has achieved the current level of -27.5 percent and possesses 63.3 percent gross margin.

Ingevity Corporation (NYSE:NGVT) is worth US$4.17 Billion and has recently risen 3.37% to US$98.25. The latest exchange of 0.23 Million shares is below its average trading activity of 230.28 Million shares. The day began at US$96.11 but the price moved to US$94.97 at one point during the trading and finally capitulating to a session high of US$98.48. The stock tapped a 52-week high of US$106.59 while the mean 12-month price target for the shares is US$104.88.

Currently, the stock carries a price to earnings ratio of 29.06, a price to book ratio of 12.79, and a price to sales ratio of 3.84. For the past 5 years, the company’s revenue has grown 0.7%, while the company’s earnings per share has grown -3.3%. With an institutional ownership near 95.7%, it carries an earnings per share ratio of 3.38.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 2 brokerage firms polled by Factset Research. At present, 3 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 3 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.12.